UDENYCA® is designed to support your patient’s treatment journey

The impact of febrile neutropenia and guidelines for treatment

Febrile neutropenia (FN) is a common and potentially life-threatening complication of chemotherapy1-3

  • For patients with cancer who visit the emergency department for FN, nearly all visits end in hospitalization4
  • FN can cause treatment delays and dose reductions, leading to negative outcomes1
hospitalIcon

AVERAGE LENGTH OF HOSPITAL STAY DUE TO FN:

5.7-9.6 days

FOR ADULTS5,6

6.2-6.8 days

FOR ELDERLY PATIENTS7

Mortality rate in adults with cancer hospitalized for neutropenia/FN:

2.6%-7.0%

(solid tumors)4,5

7.4%

(hemotologic malignancies)4

Disease-related factors that increase the likelihood of hospitalization for neutropenia/FN include:

  • Older age
  • Presence of comorbidities
  • Advanced-stage disease
  • First-cycle chemotherapy with average relative dose intensity ≥85%3,4

FN can result in a high cost to the healthcare system

fnDeskfnDesk

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendation for G-CSF use during chemotherapy8

G-CSF (e.g., pegfilgrastim) primary prophylaxis may support optimal dose intensity and clinical outcomes in certain patients undergoing myelosuppressive chemotherapy.9

When FN risk is >20%, G-CSF prophylaxis*9:

risk2

Reduced the risk of FN9

(RR: 0.54; 95% CI, 0.43-0.67)

risk1

Significantly improved the relative dose intensity (RDI) of chemotherapy with an average difference in RDI of 8.4%9

(G-CSF-treated patients vs non-G-CSF-treated patients)

G-CSF was shown to increase RDI and is associated with survival benefit†9

Important considerations

*Results from a systematic review of 17 randomized trials, which included 3493 patients with solid tumors and lymphoma. G-CSF included filgrastim and pegfilgrastim.

†Survival benefit not included in UDENYCA® prescribing information.

CI = confidence interval; G-CSF = granulocyte colony stimulating factor; RR = relative risk.

THREE ADMINISTRATION OPTIONS

THREE ADMINISTRATION OPTIONS

Multiple administration options allow you to prescribe based on the needs of your patients.

Explore administration optionsArrow
ESTABLISHED OUTCOMES

ESTABLISHED OUTCOMES

UDENYCA® was demonstrated to be highly similar to Neulasta®, with no clinically meaningful differences.10,11

Review clinical dataArrow